2 Result: SCYNEXIS
Q2: SCYNEXIS Surpasses Forecasts; Nogin Misses the Mark
August 14th, 2023
SCYNEXIS, Inc. (Nasdaq: SCYX), a biotechnology company, reported second-quarter 2023 earnings of $2.46 per share, surpassing the consensus estimate of $1.55 per share. The company posted quarterly sales of $131.50 million, exceeding analysts' project. Read more
Major Announcements in the Industry: Momentus Secures SpaceX Deal, Clearmind Medicine Receives Trial Approval, and SCYNEXIS Enters Exclusive License Agreement with GSK
May 12th, 2023
In recent updates, several companies have made significant announcements in their respective fields. Here's a breakdown of the latest developments: Momentus Inc. (Nasdaq: MNTS) has entered into a contract with SpaceX, securing a port reservation o. Read more
Want To Find Some News?
News By Industries
Recent Post
-
CSX, VinFast Auto, and Crown Castle's Earnings Preview
April 14th, 2024Earnings Spotlight: McCormick, TD SYNNEX, and GameStop Set to Report
March 23rd, 2024Upcoming Earnings: Adobe, Ulta Beauty, and Smartsheet Under the Lens
March 10th, 2024
Member Login